DGK-ι Inhibitors
DGK-ι inhibitors belong to a class of chemical compounds that specifically target diacylglycerol kinase iota (DGK-ι), an enzyme involved in the regulation of cellular signaling pathways. Diacylglycerol kinases (DGKs) constitute a family of enzymes responsible for modulating intracellular levels of diacylglycerol (DAG), a crucial lipid second messenger. DGK-ι, a member of this family, plays a pivotal role in cellular processes by influencing the balance of DAG and phosphatidic acid (PA). By selectively inhibiting DGK-ι, these inhibitors act as pharmacological tools to dissect the intricate signaling cascades in which DGK-ι is implicated.
DGK-ι inhibitors involves interfering with the catalytic activity of the enzyme, preventing the conversion of DAG to PA. This alteration in lipid metabolism has downstream effects on various signaling pathways, potentially impacting cellular functions such as proliferation, differentiation, and apoptosis. Researchers are actively exploring the specific molecular interactions between DGK-ι and its inhibitors to elucidate the structural basis of their binding. Understanding these interactions at the atomic level can provide valuable insights into the design and optimization of DGK-ι inhibitors for future research purposes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R 59-022 | 93076-89-2 | sc-203227 | 5 mg | $124.00 | 1 | |
R 59-022 is a diacylglycerol kinase inhibitor that can reduce the conversion of diacylglycerol (DAG) to phosphatidic acid (PA), potentially decreasing DGKI activity. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Taxol stabilizes microtubules and can indirectly affect DGKI by altering cellular processes and signaling pathways that may involve DGKI. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
Calphostin C is a potent inhibitor of protein kinase C (PKC) and can indirectly affect DGKI activity by modulating the DAG signaling pathway. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $90.00 $194.00 $510.00 $2448.00 $9384.00 $15300.00 | 2 | |
D-erythro-Sphingosine competes with DAG for binding to protein kinase C, which may indirectly decrease DGKI activity by altering DAG availability. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
D609 is a phosphatidylcholine-specific phospholipase C inhibitor that can indirectly inhibit DGKI by altering phosphatidic acid levels. | ||||||
Ritanserin | 87051-43-2 | sc-203681 sc-203681A | 10 mg 50 mg | $89.00 $312.00 | 2 | |
Ritanserin, a serotonin receptor antagonist, has been shown to inhibit DGK in platelets, and could thereby have an indirect effect on DGKI. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
Lyso-phosphatidic acid (Lyso-PA) can act as a PA analogue and potentially inhibit DGKI by competing with the enzyme's substrate. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Pertussis toxin can inhibit G-proteins and consequently may have an indirect effect on DGKI by altering downstream signaling pathways. | ||||||